{
  "docId": "019de075-cd17-7685-9273-fb1c731af40f",
  "docSlug": "16b2d7592f4634ac7cd717a996934f07",
  "documentTitle": "Theravance Biopharma | Results Presentation Deck | 35 slides",
  "authorId": "theravance-biopharma",
  "authorName": "Theravance Biopharma",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 6,
  "pageCount": 35,
  "prevPage": 5,
  "nextPage": 7,
  "slideType": "cover",
  "function": "front_matter",
  "density": "balanced",
  "nDataPoints": 2,
  "notes": "Slide serves as a product introduction/cover slide for a corporate presentation.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-cd17-7685-9273-fb1c731af40f/6",
  "deckHref": "/decks/019de075-cd17-7685-9273-fb1c731af40f",
  "deckJsonHref": "/decks/019de075-cd17-7685-9273-fb1c731af40f.json",
  "deckAnchorHref": "/decks/019de075-cd17-7685-9273-fb1c731af40f#slide-6",
  "components": [
    {
      "bbox": {
        "x": 0.06,
        "y": 0.16
      },
      "kind": "image",
      "text": "YUPELRI logo",
      "attrs": null,
      "subkind": "logo",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "30a98d0f-5b0e-43ae-af74-813272b92c63",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "x": 0.01,
        "y": 0.91
      },
      "kind": "image",
      "text": "Theravance Biopharma logo",
      "attrs": null,
      "subkind": "logo",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "523ac10c-9103-44fd-a4f4-bb1fcfa6b4d6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "x": 0.07,
        "y": 0.53
      },
      "kind": "list",
      "text": "FDA-approved for maintenance treatment of COPD\nFirst and only once-daily, LAMA (long-acting muscarinic agent) nebulized maintenance medicine for COPD\nCo-promotion agreement with VIATRISTM (35% / 65% Profit Share)",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ed2c8f8f-55f2-49ef-bb4e-e19b1f24ac3a",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 10,
      "from": 6,
      "beatId": "1fbb30a4-8963-45ab-9835-718fe3d33065",
      "arcName": "Monroe's Motivated Sequence",
      "arcSlug": "monroes-sequence",
      "beatName": "Need",
      "beatSlug": "monroes-sequence-need",
      "evidence": "The document highlights the addressable population for YUPELRI and the unmet need for MSA patients",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Complication",
      "parentBeatSlug": "complication"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}